| POSTER
WALKING TOUR: Contrast Agents Monday, 24
May 1999 Chairs: Jeff W.M. Bulte and Friedrich Cavagna |
| 14:00 716. Dependence of Tumor Vascular Volume and Permeability on Radiation Treatment: Assessment by Contrast Agents of Various Molecular Weights. M-Y. Su, H. Yu and O. Nalcioglu, University of California, Irvine, CA, USA. |
| 14:04 717. Dynamic Contrast-Enhanced MR Imaging of Abscess and VX2 Carcinoma in Rabbits: Comparison of 24 Gadolinium-DOTA-Dendrimer and Gadopentetate Dimeglumine, W.K. Moon, K.H. Chang and H.J. Weinmann, Seoul National University Hospital, Seoul, Korea and Schering AG, Berlin, Germany. |
| 14:08 718. The Development of a Tumor Targeting Magnetic Resonance Contrast Agent Utilizing the High Affinity Folate Receptor, S.D. Konda, M. Aref and E.C. Wiener, University of Illinois at Urbana-Champaign, Urbana, IL, USA. |
| 14:12 719. Kinetic Study of a New Contrast Agent for Brain MR Imaging on a Rat C6 Glioma Model, E. Fonchy, C. R�my, A. Fran�ois-Joubert, H. Lahrech, C. Rubin, R. Dupeyre, M. D�corps and S. Benderbous, INSERM, Grenoble, France and Laboratoire GUERBET, Aulnay-sous-bois, France. |
| 14:16 720. Contrast Enhanced MRI of Implanted VX2 Tumors in Rabbit Muscle: Comparison of Gd-DTPA and NMS60, A.J. de Crespigny, D. Howard, H. Muller, H.E. D'Arceuil, S. Seri, Y. Hashiguchi, C. Fujimoto, A. Nakatani and M.E. Moseley, Stanford University, Stanford, CA, USA; Muller Associates, Palo Alto, CA, USA and Nihon Medi-Physics Co. Ltd., Chiba, Japan. |
| 14:20 721. MR Lymphangiography: Use of Intradermal Injections of Combidex� Magnetite Nanoparticles to Visualize Lymphatic Ducts, J.M. Rogers, C.W. Jung and E.V. Groman, Advanced Magnetics, Inc., Cambridge, MA, USA. |
| 14:24 722. Contrast-Enhanced MRI: Measurement of Angiogenesis in the Wound Healing Process, T.H. Helbich, T.P. Roberts, M.D. Rollins, D.M. Shames, K. Turetschek, H.W. Hopf, M. M�hler, T.K. Hunt and R.C. Brasch, University of California, San Francisco, CA, USA. |
| 14:28 723. In Vitro Characterization of MS-325 by Multinuclear Relaxometry, R.N. Muller, B. Rad�chel, S. Laurent, J. Platzek, C. Pi�rart, P. Mareski and L. Vander Elst, University of Mons-Hainaut, Mons, Belgium and Schering AG, Berlin, Germany. |
| 14:32 724. T1 and T2 NMRD Studies of Angiomark™ (MS-325), P. Caravan, J.W.M. Bulte, S.U. Dunham, J. Amedio and R.B. Lauffer, EPIX Medical Inc., Cambridge, MA, USA and National Institutes of Health, Bethesda, MD, USA. |
| 14:36 725. Paramagnetic Liposomes as Thermosensitive Probes for MRI In Vitro Feasibility Studies, S.L. Fossheim, K.A. Il'yasov, U.N. Wiggen, A. Rogstad, J. Hennig, J. Klaveness and A. Bj�rnerud, Nycomed Imaging AS, Oslo, Norway; University of Freiburg, Freiburg, Germany and University of Oslo, Oslo, Norway. |
| 14:40 726. CBV Measurements with Steady-State Susceptibility Contrast: The Interest of Simultaneous and DR2 and DR2* Measurements, I. Tropr�s, E. Grillon, S. Grimault, C. Dolbec, H. Reutenauer and M. D�corps, Centre Hospitalier Universitaire, Grenoble, France. |
| 14:44 727. Cerebral Blood Volume in Permanent Focal Cerebral Ischemia in Rat Studied with the Steady State Susceptility-Contrast Imaging, H. Seegers, I. Tropres, E. Grillon, H. Reutenauer, A. Jaillard, M. D�corps and M. Hommel, University Hospital, Grenoble, France. |